Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

Joël Shapiro(The Netherlands Cancer Institute), Ate van der Gaast(Erasmus MC), Ernst Jan Spillenaar Bilgen(Radboud University Nijmegen), Geke A.P. Hospers(University Medical Center Groningen), Mark I. van Berge Henegouwen(University of Namur), Jannet C. Beukema(University Medical Center Groningen), Geert-Jan Creemers, Tom Rozema(Radboud University Nijmegen), R.J.B. Blaisse(Rijnstate Hospital), Bas P. L. Wijnhoven(Erasmus MC Cancer Institute), Hanneke W.M. van Laarhoven(Dutch Cancer Society), Grard A. P. Nieuwenhuijzen(Radboud University Nijmegen), Olivier R. Busch(Amsterdam Neuroscience), Cornelis J.A. Punt(Utrecht University), Herman van Dekken(Erasmus MC), Johannes J. Bonenkamp, Miguel A. Cuesta(Hospital General Universitario de Albacete), Pieter van Hagen(Erasmus MC), Janny G. Reinders(Dutch Art Institute), J. Jan B. van Lanschot(Erasmus MC Cancer Institute), John Th. M. Plukker(University Medical Center Groningen), Maarten C.C.M. Hulshof(Academic Medical Center), Henk M.W. Verheul(Erasmus MC Cancer Institute), Ewout W. Steyerberg(Erasmus MC), Anna H.M. Piet(Amsterdam University Medical Centers), Hugo W. Tilanus(Amsterdam UMC Location University of Amsterdam), Caroline M. van Rij(Erasmus MC), Katharina Biermann(Erasmus University Rotterdam), Fiebo J.W. ten Kate, Maurice J.C. van der Sangen(Radboud University Nijmegen)
The Lancet Oncology
August 6, 2015
Cited by 2,590


Related Papers